Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05765201
Other study ID # Alcon IIT # 75098433
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 22, 2022
Est. completion date May 4, 2023

Study information

Verified date January 2024
Source Wolfe Eye Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate the anterior and posterior structure and functional changes and vascular alterations when performing phacoemulsification at high IOP vs low, more physiological IOP using Centurion® Vision System with Active Sentry® handpiece. These devices are approved by the US Food and Drug Administration (FDA).


Description:

To investigate the anterior and posterior physiological changes when performing phacoemulsification at high IOP vs low, more physiologic IOP using Centurion® Vision System with Active Sentry® handpiece Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye Operating at lower, more physiological IOP using Active Sentry® handpiece during cataract surgery will use less BSS fluid usage. (Lower IOP settings are also expected to result in less subclinical changes).


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date May 4, 2023
Est. primary completion date May 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - No prior ocular surgery including corneal refractive surgery - Bilateral visually significant cataract, similar in density (LOCS III grade 2+), undergoing uncomplicated cataract surgery - Equal dilated pupil size =6mm, no use of pupil expansion devices - Unremarkable systemic health but inclusive of controlled type II diabetes and hypertension with normal OCT angiography at baseline - A1C = 8% on single monotherapy or lifestyle adjustments - To maintain high sensitivity/specificity, patients to fall under OCT normative database: - Axial length 22-26mm - Refractive error between -5.00D to +5.00D - Cylinder = 3.00D - Normal K values <47.00D - Axial eye length cannot vary by more than 0.4 mm in an individual patient - Normal CCT range 540µm ± 50 Exclusion Criteria: - H/o corneal disease or dystrophies - Media opacification for reasons other than cataract - Compromised zonular integrity or stability - Retinal and retinal vascular pathologies, age-related macular degeneration - Glaucoma - Patients with uncontrolled systematic diseases; including hypertension, diabetes, systemic cardiovascular diseases and hematological diseases

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High IOP
Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP = 28mmHg (low IOP) in one eye and with IOP = 60mmHg (high IOP) in the other eye
Low IOP
Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP = 28mmHg (low IOP) in one eye and with IOP = 60mmHg (high IOP) in the other eye

Locations

Country Name City State
United States Wolfe Eye Clinic West Des Moines Iowa

Sponsors (1)

Lead Sponsor Collaborator
Matthew Rauen

Country where clinical trial is conducted

United States, 

References & Publications (6)

Chen D, Zhu J, Li J, Ding XX, Lu F, Zhao YE. Effect of simulated dynamic intraocular pressure on retinal thickness measured by optical coherence tomography after cataract surgery. Int J Ophthalmol. 2012;5(6):687-93. doi: 10.3980/j.issn.2222-3959.2012.06.0 — View Citation

Li T, Guadie A, Feng L, Fan J, Jiang Z, Liu F. Influence of cataract surgery on macular vascular density in patients with myopia using optical coherence tomography angiography. Exp Ther Med. 2020 Dec;20(6):258. doi: 10.3892/etm.2020.9388. Epub 2020 Oct 27 — View Citation

Liu X, Fang Y, Zhou Y, Wang M, Luo Y. Dynamic changes in retinal vessel density observed by optical coherence tomography angiography after phacoemulsification: active vs gravity fluidics system. Arq Bras Oftalmol. 2022 Apr 8;85(2):205-207. doi: 10.5935/00 — View Citation

Tang Y, Chen X, Zhang X, Tang Q, Liu S, Yao K. Clinical evaluation of corneal changes after phacoemulsification in diabetic and non-diabetic cataract patients, a systematic review and meta-analysis. Sci Rep. 2017 Oct 26;7(1):14128. doi: 10.1038/s41598-017 — View Citation

Vasavada V, Raj SM, Praveen MR, Vasavada AR, Henderson BA, Asnani PK. Real-time dynamic intraocular pressure fluctuations during microcoaxial phacoemulsification using different aspiration flow rates and their impact on early postoperative outcomes: a ran — View Citation

Zeng S, Liang C, He Y, Chen Y, Zhao Q, Dai S, Cheng F, Zhang J, Jiang X. Changes of Subfoveal Choroidal Thickness after Cataract Surgery: A Meta-Analysis. J Ophthalmol. 2018 Nov 12;2018:2501325. doi: 10.1155/2018/2501325. eCollection 2018. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Estimated fluid usage- High IOP Group Measurement of fluid usage (ml). Intraoperative
Primary Estimated fluid usage- Low IOP Group Measurement of fluid usage (ml). Intraoperative
Secondary Macular Thickness Macular thickness measured in microns at week 1, month 1, and month 3. Measured by optical coherence tomography (OCT). post procedure at 1 week, 1 month, and 3 months
Secondary Corneal Thickness Corneal thickness measured in microns at 1 day, week 1, month 1, and month 3. Measured by pentacam tomography. post procedure at 1 day, 1 week, 1 month, and 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06325397 - Less Discomfort and Less Pharmacology. Cataract Surgery at Physiologic Intraocular Pressure (IOP)
Active, not recruiting NCT00825721 - Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract Phase 2
Completed NCT04975971 - A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
Recruiting NCT05736042 - Microinterventional Endocapsular Nuclear Fragmentation Assisted Cataract Surgery N/A